Global reported impacts of <scp>COVID</scp>‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic

Elliott, Esther K; Hensen, Robert; Haupt, Larisa M.; Griffiths, Lyn R.

doi:10.1111/ejh.13926

Cited by 3 publications

(1 citation statement)

References 65 publications

(123 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, patients with lymphoma have compromised immune systems both due to the lymphoma itself and the immunosuppressive treatment. Several studies have reported a more severe COVID-19 trajectory among patients with lymphoma compared to the general population and also compared to patients with solid organ cancer [10,11].…”

Section: Introductionmentioning

confidence: 99%

Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival – a Swedish Lymphoma Register Study

Ekberg,

Molin,

Pahnke

et al. 2024

View full text Add to dashboard Cite

Background & purpose: The COVID-19 pandemic posed a large challenge for healthcare systems across the world. Comprehensive data on the impact of the COVID-19 pandemic on incidence and mortality in lymphoma are lacking. Patients/methods: Using data from the Swedish lymphoma register, we compare incidence and 1-year survival of lymphoma patients in Sweden before (2017–2019) and during the pandemic (2020 and 2021). Results: Fewer patients were diagnosed with lymphomas during March–June 2020, but the annual incidence rates for 2020 and 2021 were similar to those of 2017–2019. A larger proportion of patients presented with stage IV disease during 2021. There were no differences in other base-line characteristics nor application of active treatment in pre-pandemic and pandemic years. One-year overall survival was not inferior among lymphoma patients during the pandemic years compared to pre-pandemic years i.e., 2017–2019. Interpretation: The COVID-19 pandemic had limited impact on the incidence and mortality of lymphoma in Sweden.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival – a Swedish Lymphoma Register Study

Ekberg,

Molin,

Pahnke

et al. 2024

View full text Add to dashboard Cite

show abstract

Risk and Severity of COVID-19 Infection in Monoclonal Gammopathy of Undetermined Significance: A 3-Year Propensity Matched Cohort Study

Ashruf

Orozco

Kaelber

2023

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Real-World Challenges of Managing Diffuse Large B-Cell Lymphoma in a Developing Country

Iftikhar,

Ahmad,

Haider

et al. 2024

JCO Glob Oncol

View full text Add to dashboard Cite

PURPOSE To highlight challenges and cancer care disparities in patients of diffuse large B-cell lymphoma management in resource-constrained settings. MATERIALS AND METHODS This multicenter retrospective study included 738 patients from 12 public and private sector hematology-oncology centers across Pakistan. Patients were divided into limited-resource and enhanced-resource settings as per national diffuse large B-cell lymphoma (DLBCL) guidelines. RESULTS The median age at diagnosis was 47 years (range, 14-89). Male:female ratio was 2.5:1. Majority of the patients (69.3%) were treated in limited-resource settings. Computed tomography was used as a staging modality in 442 (60%) patients. Limited-stage DLBCL was present in 13.5% of patients, while 86.3% had advanced-stage disease at diagnosis. First-line regimens included rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in 56% and cyclophosphamide, doxorubicin, vincristine, prednisone in 34% of patients, while 10% of patients received palliative regimens upfront. Of evaluable data, complete remission was documented in 299 (74.4%) patients, 39 (9.8%) had partial response and 63 (13.5%) had progressive disease. Disease-free survival (DFS) and overall survival (OS) status were not available for 345 (46.8%) patients at the time of data collection. Overall study cohort had a median follow-up of 2.2 years with a median OS of 3.6 years (95% CI, 3.1 to 4.1), median DFS of 3.1 years (95% CI, 2.6 to 3.6), and a 5-year OS of 40% and DFS of 36%. CONCLUSION Patients from low- and middle-income countries present at an earlier age and have more advanced disease. Patients were frequently lost to follow-up, and record keeping was inadequate more so in patients treated in limited-resource settings. There is a need to establish a national lymphoma registry, improve record keeping, and standardize treatments to ensure improvement in treatment outcomes.

show abstract

Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic

Cited by 3 publications

References 65 publications

Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival – a Swedish Lymphoma Register Study

Impact of the COVID-19 pandemic on lymphoma incidence and short-term survival – a Swedish Lymphoma Register Study

Risk and Severity of COVID-19 Infection in Monoclonal Gammopathy of Undetermined Significance: A 3-Year Propensity Matched Cohort Study

Real-World Challenges of Managing Diffuse Large B-Cell Lymphoma in a Developing Country

Contact Info

Product

Resources

About